TNF and myeloid sarcoma: Additional proteomic screening studies and evaluation of TNFα and miR-130a-3p expression levels in a larger population are necessary to identify biomarkers and post-translational modifications to understand their ability to differentiate whether patients are in the RRMS course or have converted to the SPMS course or are in the impending flare-up of MS.